Active Specific Immunotherapy Phase III Trials for Malignant Melanoma: Systematic Analysis and Critical Appraisal

Journal of the American College of Surgeons

Volumn 207, Issue 1, 2008, Pages 95-105

  Rosenthal, Rachel ^a   Viehl, Carsten T ^b   Guller, Ulrich ^b   Weber, Walter P ^b   Adamina, Michel ^b   Spagnoli, Giulio C ^b   Heberer, Michael ^b   Zuber, Markus ^a  

^a Kantonspital Olten ^*  (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALPHA METHYL 2 BETA,17 BETA DIHYDROXY 5 ALPHA ANDROSTANE; 2 AMINOMETHYLENE 17 ALPHA METHYL 17 BETA HYDROXY 5 ALPHA ANDROSTAN 3 ONE; ALPHA2B INTERFERON; ANDROSTANOLONE DERIVATIVE; BCG VACCINE; CANCER VACCINE; CANVAXIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DENDRITIC CELL VACCINE; GANGLIOSIDE; GMK VACCINE; INTERLEUKIN 2; MELACINE; PHOSPHORYL LIPID A; PLACEBO; TAMOXIFEN; TESTOSTERONE; TUMOR ANTIGEN; VACCINIA VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER STAGING; CANCER SURVIVAL; CELL LYSATE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DENDRITIC CELL; DRUG WITHDRAWAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; INCIDENCE; LOW DRUG DOSE; MELANOMA; META ANALYSIS; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; DACARBAZINE; DENDRITIC CELLS; EPITOPES; GANGLIOSIDES; IMMUNOTHERAPY, ACTIVE; INTERFERONS; MELANOMA; VACCINIA VIRUS;

EID: 45849132702     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2008.01.024     Document Type: Review

References (51)

1. Lamberg L. "Epidemic" of malignant melanoma: true increase or better detection?. JAMA 287 (2002) 2201
2. Cancer facts & figures 2006. http://www.cancer.org Accessed March 12, 2008
3. Verma S., Quirt I., McCready D., et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 106 (2006) 1431-1442
4. Komenaka I., Hoerig H., and Kaufman H.L. Immunotherapy for melanoma. Clin Dermatol 22 (2004) 251-265
5. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14 (1996) 7-17
6. Van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
7. Wallack M.K., Sivanandham M., Balch C.M., et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double. blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187 (1998) 69-79
8. Mitchell M.S., and Von Eschen K.B. Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Proc Am Soc Clin Oncol 16 (1997) 494a (abstr 1778)
9. Sondak V.K., Liu P.Y., Tuthill R.J., et al. Adjuvant immunotherapy of resected, intermediate thickness, node-negative malnoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20 (2002) 2058-2066
10. Hersey P., Coates A.S., McCarthy W.H., et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 20 (2002) 4181-4190
11. ™), compared to placebo as a post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol 13 (2006) 5 (abstr 12)
12. Livingston P.O., Wong G.Y.C., Adluri S., et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12 (1994) 1036-1044
13. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 (2001) 2370-2380
14. Schadendorf D., Ugurel S., Schuler-Thurner B., et al. DC study group of the DeCOG Dacarbazin (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17 (2006) 563-570
15. Wallack M.K., Meyer M., Bourgoin A., et al. A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment. J Biol Response Mod 2 (1983) 586-596
16. Wallack M.K., Bash J.A., Leftheriotis E., et al. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg 122 (1987) 1460-1463
17. Wallack M.K., McNally K.R., Leftheriotis E., et al. A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. Cancer 57 (1986) 649-655
18. Wallack M.K., Sivanandham M., Balch C.M., et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75 (1995) 34-42
19. Wallack M.K., Sivanandham M., Whooley B., et al. Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial. Ann Surg Oncol 3 (1996) 110-117
20. Wallack M.K., Sivanandham M., Ditaranto K., et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg 226 (1997) 198-206
21. Mitchell M.S., Kan-Mitchell J., Kempf R.A., et al. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48 (1988) 5883-5893
22. Mitchell M.S., Harel W., Kemph R.A., et al. Active-specific immunotherapy for melanoma. J Clin Oncol 8 (1990) 856-869
23. Mitchell M.S., Harel W., and Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 10 (1992) 1158-1164
24. Sosman J.A., Unger J.M., Liu P.Y., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 20 (2002) 2067-2075
25. Hersey P., Edwards A., Coates A., et al. Evidence that treatment with vaccinia melanoma cells lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Immunol Immunother 25 (1987) 257-265
26. Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J Surg 16 (1992) 251-260
27. Berd D., Maguire Jr. H.C., and Mastrangelo M.J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46 (1986) 2572-2577
28. Morton D.L., Hsueh E.C., Essner R., et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236 (2002) 438-449
29. Hsueh E.C., Essner R., Foshag L.J., et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20 (2002) 4549-4554
30. Hamilton W.B., Helling F., Lloyd K.O., and Livingston P.O. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 53 (1993) 566-573
31. Livingston P. Ganglioside vaccines with emphasis on GM2. Semin Oncol 25 (1998) 636-645
32. Livingston P.O., Natoli E.J., Calves M.J., et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84 (1987) 2911-2915
33. Livingston P.O., Ritter G., Srivastava P., et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49 (1989) 7045-7050
34. Spagnoli G.C., Adamina M., Bolli M., et al. Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation. World J Surg 29 (2005) 692-699
35. Monsurro V., Wang E., Panelli M.C., et al. Active-specific immunization against melanoma: is the problem at the receiving end?. Semin Cancer Biol 13 (2003) 473-480
36. Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 (1998) 328-332
37. Guller U., and Oertli D. Sample size matters: a guide for surgeons. World J Surg 29 (2005) 601-605
38. Guller U. Surgical outcomes research based on administrative data: inferior or complementary to prospective randomized clinical trials?. World J Surg 30 (2006) 255-266
39. Guller U., and DeLong E.R. Interpreting statistics in medical literature: a vade mecum for surgeons. J Am Coll Surg 198 (2004) 441-458
40. Sondak V.K. Multi-institutional melanoma vaccine trial. Ann Surg Oncol 3 (1996) 588-589
41. Berzofsky J.A., Ahlers J.D., and Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1 (2001) 209-219
42. Thomas C.E., Ehrhardt A., and Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4 (2003) 346-358
43. O'Hagan D.T., and Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2 (2003) 727-735
44. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
45. Fehniger T.A., Cooper M.A., and Caligiuri M.A. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 13 (2002) 169-183
46. Barber D.L., Wherry E.J., Masopust D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006) 682-687
47. Day C.L., Kaufmann D.E., Kiepiela P., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 (2006) 350-354
48. Peggs K.S., Quezada S.A., Korman A.J., and Allison J.P. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18 (2006) 206-213
49. De Libero G., and Mori L. Recognition of lipid antigens by T cells. Nat Rev Immunol 5 (2005) 485-496
50. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
51. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al., Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672